Highlights PaxMedica, Inc.

Equities

PXMD

US70424C2035

Delayed OTC Markets Other stock markets 11:26:33 2024-05-14 EDT			5-day change	1st Jan Change
0.2129 ^USD	-6.95%		-15.85%	-71.88%

05-06	PaxMedica, Inc.(NasdaqCM:PXMD) dropped from S&P TMI Index	CI
05-01	PaxMedica, Inc.(NasdaqCM:PXMD) dropped from NASDAQ Composite Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Paxmedica, Inc. Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101	04-23	CI
PaxMedica, Inc. Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness	04-16	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	04-12	MT
Top Midday Gainers	04-12	MT
Major US Banks' Lower Earnings Drag Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday	04-12	MT
PaxMedica, Inc. Achieves Key Milestone in the Development of Pax-101 and Provides Update on Potential NDA Submission	04-11	CI
PaxMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
PaxMedica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
PaxMedica, Inc. acquired Certain Suramin Research Assets from Rediscovery Life Sciences AKI LLC for $0.1 million.	23-10-30	CI
Paxmedica, Inc. Holds Important Fda Type-B Meeting to Review Pax-101 Pivotal Trial Data	23-10-26	CI
PaxMedica, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
PaxMedica, Inc. Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301	23-07-24	CI
PaxMedica, Vox Nova in Pharmacy Distribution Deal for PAX-101 in US	23-07-06	MT
PaxMedica, Inc. Submits Request to South African Health Products Regulatory Authority, Seeking Approval to Conduct Double-Blind, Placebo-Controlled Study, PAX-ASD-101	23-06-14	CI
PaxMedica, Inc. Enters Research Collaboration Agreement with PoloMar Health for Phase II Study in Autism Spectrum Disorder	23-06-08	CI
PaxMedica Signs Research Deal With PoloMar Health for Mid-Stage Autism Spectrum Disorder Trial	23-06-08	MT
PaxMedica, Inc. Completes Efficacy Review and Final Enrollment for the Company's Real World Evidence Study (HAT-301)	23-06-02	CI
PaxMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month	23-04-19	AQ
PaxMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PaxMedica, Inc.

Equities

PXMD

US70424C2035

Highlights

Filters